Categorized | Melanoma News, Of Interest

Obesity Linked to Improved Outcomes in Men With Metastatic Melanoma

Source: OncLive, March 2018

Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI, according to results from a retrospective multicohort analysis published in The Lancet Oncology.1
In obese male patients treated with either targeted therapy or immunotherapy, median overall survival (OS) was almost double that of patients with normal a BMI (HR, 0.53; 95% CI, 0.40-0.70; P = .04). BMI from 18.5 to 24.9 kg/m2 was considered normal. BMI ?30 kg/m2 was considered obese.
Investigators found no significant differences in survival between women with normal, overweight, or obese BMI (HR, 0.85; 95% CI, 0.61-1.18, Pinteraction = .03). Median OS was at least 33 months for all women in the study.
read the original full article